Horizon Therapeutics Plc (HZNP)

27.27
0.77 2.91
NASDAQ : Health Technology
Prev Close 26.50
Open 26.52
Day Low/High 26.46 / 27.44
52 Wk Low/High 16.56 / 29.44
Volume 1.77M
Avg Volume 1.82M
Exchange NASDAQ
Shares Outstanding 186.45M
Market Cap 4.92B
EPS -0.50
P/E Ratio 68.38
Div & Yield N.A. (N.A)
5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

5 High Growth Healthcare Stocks With Heavy Insider Buying

5 High Growth Healthcare Stocks With Heavy Insider Buying

Are you looking to diversify with high growth stocks in the healthcare sector? The following stock list, which accounts for [...]

Commit To Buy Horizon Pharma At $1, Earn 15%

Commit To Buy Horizon Pharma At $1, Earn 15%

Investors considering a purchase of Horizon Pharma Inc stock, but cautious about paying the going market price of $2.30/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $1 strike, which has a bid at the time of this writing of 15 cents.

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

January Effect Stock Picks Here Are 7 Possible Winners For 2013

January Effect Stock Picks Here Are 7 Possible Winners For 2013

Last year I presented a basket of stocks we believed were trading below value as a result of the January [...]

Shorting Alexza Pharma On FDA's Adasuve Approval

Shorting Alexza Pharma On FDA's Adasuve Approval

Alexza is setting up as a classic biotech run-down stock, says trader Mark Messier.

11 Stocks With Significant Institutional And Insider Buying

11 Stocks With Significant Institutional And Insider Buying

Looking for stocks with bullish sentiment from both insiders and hedge funds? If so, you will likely find this list [...]

10 Stocks With Bullish Institutional And Insider Buying Activities

10 Stocks With Bullish Institutional And Insider Buying Activities

Looking for popular stocks with big potential upside? We find that stocks receiving bullish attention from company insiders and hedge [...]

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

A Look at What the Big Boys Have Been Buying

Here are five large purchases that were made by hedge funds recently.

Horizon Pharma's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Horizon Pharma's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Horizon Pharma's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Biotech Stock Mailbag: Amarin, Sarepta

Biotech Stock Mailbag: Amarin, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Horizon Pharma: Rayos FDA Approval Thursday Seems Likely

Horizon Pharma: Rayos FDA Approval Thursday Seems Likely

Horizon will sell Rayos as a morning pain relief for patients with rheumatoid arthritis.

28 Drugs Facing FDA Approval in 2012-2013

28 Drugs Facing FDA Approval in 2012-2013

An updated calendar listing FDA drug approval decisions and advisory panels for the remainder of 2012 and early 2013

Navigating a Sea of Red

The market is starting to stabilize, but the action remains skittish.

A Busy Week For Bio-Pharma Earnings, Drug Approvals

A Busy Week For Bio-Pharma Earnings, Drug Approvals

Highlights include the Amarin's FDA drug approval decision and earnings from Celgene, Amgen, Biogen Idec and Gilead Sciences.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Seems Like a Run-of-the-Mill Pullback

There is no reason to believe the market is topping out. It just needs to digest its gains.

The Next Big Thing in Biotech: Amarin, Onyx

The Next Big Thing in Biotech: Amarin, Onyx

Adam Feuerstein, senior columnist for TheStreet, says Amarin and Onyx are the next big things in biotech.

Delayed Reaction

The weak ISM number will eventually matter, but for now, traders are focused on technical conditions.

Four Drug Stocks Facing FDA Approval Decisions in July

Four Drug Stocks Facing FDA Approval Decisions in July

Vivus, Amarin, Horizon Pharma and Onyx Pharma are expecting FDA drug approval decisions in July.

Risk Is High

But you can deal with it by playing fast and tight.

7 Stocks Under $10 Soaring Higher

7 Stocks Under $10 Soaring Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look poised to break out and trade higher from current levels.

Healthcare IPOs: Horizon, WhiteGlove

Healthcare IPOs: Horizon, WhiteGlove

Investors are taking their chances if they jump in and buy shares in these unproven IPOs.

TheStreet Quant Rating: C+ (Hold)